Antibody-drug conjugates--an emerging class of cancer treatment

Br J Cancer. 2016 Feb 16;114(4):362-7. doi: 10.1038/bjc.2015.435. Epub 2016 Jan 7.


Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Immunoconjugates / chemistry
  • Immunoconjugates / therapeutic use*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology


  • Antibodies, Monoclonal
  • Immunoconjugates